RS56066B2 - Supstituisani ksantini i postupci za njihovu upotrebu - Google Patents

Supstituisani ksantini i postupci za njihovu upotrebu

Info

Publication number: RS56066B2
Authority: RS; Serbia
Prior art keywords: methods; substituted xanthines; xanthines; substituted
Prior art date: 2013-03-15

Application number

RS20170566A

Other languages

English (en)

Inventor

Bertrand Chenard

Randall Gallaschun

Original Assignee

Hydra Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2014-03-14

Publication date

2018-09-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS56066(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-14 Application filed by Hydra Biosciences Inc filed Critical Hydra Biosciences Inc

2017-10-31 Publication of RS56066B1 publication Critical patent/RS56066B1/sr

2018-09-28 Publication of RS56066B2 publication Critical patent/RS56066B2/sr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epidemiology (AREA)
Silver Salt Photography Or Processing Solution Therefor (AREA)
Thiazole And Isothizaole Compounds (AREA)
Medicinal Preparation (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

RS20170566A 2013-03-15 2014-03-14 Supstituisani ksantini i postupci za njihovu upotrebu RS56066B2 (sr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361789724P	2013-03-15	2013-03-15
PCT/US2014/027920 WO2014143799A2 (en)	2013-03-15	2014-03-14	Substituted xanthines and methods of use thereof
EP14722452.1A EP2970303B3 (en)	2013-03-15	2014-03-14	Substituted xanthines and methods of use thereof

Publications (2)

Publication Number	Publication Date
RS56066B1 RS56066B1 (sr)	2017-10-31
RS56066B2 true RS56066B2 (sr)	2018-09-28

Family

ID=50680155

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20170566A RS56066B2 (sr)	2013-03-15	2014-03-14	Supstituisani ksantini i postupci za njihovu upotrebu

Country Status (32)

Country	Link
US (7)	US9359359B2 (sr)
EP (1)	EP2970303B3 (sr)
JP (1)	JP6360149B2 (sr)
KR (1)	KR102227629B1 (sr)
CN (2)	CN105143229B (sr)
AU (1)	AU2014228206C1 (sr)
CA (1)	CA2899646C (sr)
CL (1)	CL2015002738A1 (sr)
CY (1)	CY1119042T1 (sr)
DK (1)	DK2970303T6 (sr)
EA (1)	EA028815B1 (sr)
ES (1)	ES2636835T7 (sr)
HK (1)	HK1217329A1 (sr)
HR (1)	HRP20170840T4 (sr)
HU (1)	HUE033528T4 (sr)
IL (1)	IL240216B (sr)
LT (1)	LT2970303T (sr)
MX (1)	MX370372B (sr)
MY (1)	MY189912A (sr)
NZ (1)	NZ711718A (sr)
PE (1)	PE20151779A1 (sr)
PH (1)	PH12015502141B1 (sr)
PL (1)	PL2970303T6 (sr)
PT (1)	PT2970303T (sr)
RS (1)	RS56066B2 (sr)
SG (1)	SG11201506479TA (sr)
SI (1)	SI2970303T1 (sr)
TW (1)	TWI609867B (sr)
UA (1)	UA117470C2 (sr)
UY (1)	UY35488A (sr)
WO (1)	WO2014143799A2 (sr)
ZA (1)	ZA201505414B (sr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8173750B2 (en)	2009-04-23	2012-05-08	ATRP Solutions, Inc.	Star macromolecules for personal and home care
RS56066B2 (sr)	2013-03-15	2018-09-28	Hydra Biosciences Inc	Supstituisani ksantini i postupci za njihovu upotrebu
EP3180342B1 (en) *	2014-08-11	2019-06-26	Hydra Biosciences, Inc.	Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
WO2016159747A1 (en)	2015-03-27	2016-10-06	Latvian Institute Of Organic Synthesis	Ethynylxanthines, preparation and use as calcium ion channel modulators
GB2553685B (en)	2015-03-27	2020-06-10	Latvian Inst Organic Synthesis	Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis
WO2016159745A1 (en)	2015-03-27	2016-10-06	Latvian Institute Of Organic Synthesis	Ethynylxanthines, preparation and use for cancer treatment
EP3280417B1 (en) *	2015-04-08	2020-07-29	Lewis and Clark Pharmaceuticals, Inc.	Xanthine-substituted alkynyl carbamates/reverse carbamates as a2b antagonists
CN107118586A (zh) *	2016-02-24	2017-09-01	中国科学技术大学	含氮杂环基取代的烯类化合物的用途
GB201702160D0 (en) *	2017-02-09	2017-03-29	Univ Leeds Innovations Ltd	Inhibitors for use in therapy
US11666577B2 (en) *	2017-02-28	2023-06-06	National Institute Of Biological Sciences, Beijing	MLKL inhibitors
CN110573509B (zh) *	2017-02-28	2023-05-26	北京生命科学研究所	Mlkl抑制剂
EP3652176B1 (en) *	2017-07-11	2021-12-15	Boehringer Ingelheim International GmbH	Substituted xanthine derivatives
CN118908961A (zh) *	2018-03-05	2024-11-08	金翅雀生物公司	咪唑并二氮杂卓二酮和其使用方法
EP3894409B1 (en) *	2018-12-12	2023-08-23	Boehringer Ingelheim International GmbH	Substituted xanthine derivatives
JP7502299B2 (ja) *	2018-12-12	2024-06-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	置換キサンチン誘導体
CN112979651B (zh) *	2021-04-09	2022-02-01	南京纽邦生物科技有限公司	一种副黄嘌呤的制备方法
CN113354646B (zh) *	2021-07-06	2022-11-15	南开大学	8-芳氧基烷氧基取代黄嘌呤衍生物及其制备方法和应用
CN115636831B (zh) *	2022-10-27	2024-11-08	中国药科大学	稠合嘧啶二酮类化合物、其用途以及药物组合物
TW202440582A (zh)	2022-12-20	2024-10-16	德商百靈佳殷格翰國際股份有限公司	７－（４－氯苯甲基）－１－（３－羥丙基）－３－甲基－８－（３－（三氟甲氧基）－苯氧基）－３，７－二氫－１ｈ－嘌呤－２，６－二酮之製備方法
WO2024153028A1 (zh) *	2023-01-20	2024-07-25	深圳晶蛋生物医药科技有限公司	大环类化合物、其药物组合物及其应用
WO2024165540A1 (en)	2023-02-06	2024-08-15	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione
WO2024164818A1 (zh) *	2023-02-08	2024-08-15	中国科学院上海药物研究所	黄嘌呤类化合物及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4304650A1 (de) *	1993-02-16	1994-08-18	Thomae Gmbh Dr K	Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6878715B1 (en) *	1994-02-18	2005-04-12	Cell Therapeutics, Inc.	Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
JP4191269B2 (ja)	1996-05-17	2008-12-03	興和株式会社	新規なアニリド化合物及びこれを含有する医薬
JPH10318487A (ja)	1997-05-16	1998-12-04	Mitsubishi Gas Chem Co Inc	真空断熱材用ゲッタ
US6075029A (en) *	1998-01-02	2000-06-13	Cell Therapeutics, Inc.	Xanthine modulators of metabolism of cellular P-450
US6187780B1 (en) *	1998-04-16	2001-02-13	Boehringer Ingelheim Pharma Kg	Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
DE60024604T2 (de) *	1999-04-09	2006-08-24	Cell Therapeutics, Inc., Seattle	Xanthinderivate und analoge als zellsignalisierung inhibitoren
IL153182A0 (en) *	2000-07-04	2003-06-24	Novo Nordisk As	Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
RU2003120061A (ru)	2000-12-07	2004-11-27	Си Ви Терапьютикс, Инк. (Us)	Замещенные 1,3,5-триазины и пиримидины в качестве повышающих авса-1 соединений против заболевания коронарной артерии или атеросклероза
HU230382B1 (hu) *	2001-02-24	2016-03-29	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként
PL370207A1 (en) *	2001-11-09	2005-05-16	Cv Therapeutics, Inc.	A2b adenosine receptor antagonists
AU2003249604B2 (en) *	2003-05-06	2011-06-30	Gilead Sciences, Inc.	A2B adenosine receptor antagonists
AU2004291102A1 (en)	2003-11-13	2005-06-02	Board Of Regents, The University Of Texas System	Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure
EP1841448A2 (en)	2004-12-30	2007-10-10	Diakine Therapeutics, Inc.	Pharmaceutical compositions and methods for restoring beta-cell mass and function
US8143254B2 (en)	2005-02-18	2012-03-27	Cornell Research Foundation, Inc.	Methods for modulating ion channels
EP2272848B1 (en) *	2005-08-10	2012-12-26	Glaxosmithkline LLC	Xanthine derivatives as selective HM74A agonists
EP1922316B1 (en)	2005-09-06	2010-03-03	GlaxoSmithKline LLC	Benzimidazole thiophene compounds as plk modulators
AU2006322349A1 (en) *	2005-12-07	2007-06-14	Ucb Pharma, S.A.	Xanthine derivatives, processes for preparing them and their uses
WO2007073505A2 (en) *	2005-12-22	2007-06-28	Hydra Biosciences, Inc.	Trpa1 inhibitors for treating pain
US20070232673A1 (en)	2006-01-19	2007-10-04	Roth Gregory P	2-Imino-benzimidazoles
WO2007101213A2 (en)	2006-02-28	2007-09-07	Kalypsys, Inc.	Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors
WO2008011518A2 (en) *	2006-07-19	2008-01-24	Diakine Therapeutics, Inc.	Encapsulation system
WO2009157938A1 (en) *	2008-06-26	2009-12-30	Cv Therapeutics, Inc.	A2b adenosine receptor antagonists for treating cancer
US20120148604A1 (en)	2009-08-20	2012-06-14	Transposagen Biopharmaceuticals, Inc.	Trp inhibitors and uses thereof
WO2011114184A1 (en) *	2010-03-15	2011-09-22	Glenmark Pharmaceuticals S.A.	Amides of heterocyclic compounds as trpa1 inhibitors
WO2012050641A2 (en)	2010-06-08	2012-04-19	Hydra Biosciences, Inc	Use of trpa1 antagonists to prevent or treat infections caused by biological-warfare agents
JP2013023102A (ja) *	2011-07-22	2013-02-04	Panasonic Corp	列車情報提供システム
WO2013023102A1 (en) *	2011-08-09	2013-02-14	Hydra Biosciences, Inc.	Inhibiting transient receptor potential ion channel trpa1
CN103121970B (zh)	2012-12-04	2015-04-29	中国科学院昆明植物研究所	苯并咪唑及其衍生物，其药物组合物及其在制备抗抑郁药物中的应用
RS56066B2 (sr)	2013-03-15	2018-09-28	Hydra Biosciences Inc	Supstituisani ksantini i postupci za njihovu upotrebu

2014
- 2014-03-14 RS RS20170566A patent/RS56066B2/sr unknown
- 2014-03-14 US US14/210,781 patent/US9359359B2/en active Active
- 2014-03-14 MX MX2015011617A patent/MX370372B/es active IP Right Grant
- 2014-03-14 JP JP2016502662A patent/JP6360149B2/ja active Active
- 2014-03-14 PT PT147224521T patent/PT2970303T/pt unknown
- 2014-03-14 KR KR1020157029667A patent/KR102227629B1/ko active IP Right Grant
- 2014-03-14 LT LTEP14722452.1T patent/LT2970303T/lt unknown
- 2014-03-14 SG SG11201506479TA patent/SG11201506479TA/en unknown
- 2014-03-14 ES ES14722452.1T patent/ES2636835T7/es active Active
- 2014-03-14 WO PCT/US2014/027920 patent/WO2014143799A2/en active Application Filing
- 2014-03-14 DK DK14722452.1T patent/DK2970303T6/en active
- 2014-03-14 SI SI201430241T patent/SI2970303T1/sl unknown
- 2014-03-14 TW TW103109651A patent/TWI609867B/zh active
- 2014-03-14 PL PL14722452T patent/PL2970303T6/pl unknown
- 2014-03-14 NZ NZ711718A patent/NZ711718A/en unknown
- 2014-03-14 HU HUE14722452A patent/HUE033528T4/en unknown
- 2014-03-14 CA CA2899646A patent/CA2899646C/en active Active
- 2014-03-14 PE PE2015001829A patent/PE20151779A1/es active IP Right Grant
- 2014-03-14 MY MYPI2015702631A patent/MY189912A/en unknown
- 2014-03-14 EP EP14722452.1A patent/EP2970303B3/en active Active
- 2014-03-14 CN CN201480023267.0A patent/CN105143229B/zh active Active
- 2014-03-14 UA UAA201507774A patent/UA117470C2/uk unknown
- 2014-03-14 EA EA201591615A patent/EA028815B1/ru not_active IP Right Cessation
- 2014-03-14 CN CN201710063554.XA patent/CN107082782B/zh active Active
- 2014-03-14 AU AU2014228206A patent/AU2014228206C1/en active Active
- 2014-03-17 UY UY0001035488A patent/UY35488A/es active IP Right Grant
2015
- 2015-07-28 ZA ZA2015/05414A patent/ZA201505414B/en unknown
- 2015-07-29 IL IL240216A patent/IL240216B/en active IP Right Grant
- 2015-09-15 PH PH12015502141A patent/PH12015502141B1/en unknown
- 2015-09-15 CL CL2015002738A patent/CL2015002738A1/es unknown
2016
- 2016-04-25 US US15/137,327 patent/US20160237089A1/en not_active Abandoned
- 2016-05-10 HK HK16105298.0A patent/HK1217329A1/zh unknown
2017
- 2017-06-01 HR HRP20170840TT patent/HRP20170840T4/hr unknown
- 2017-06-14 US US15/622,838 patent/US9969736B2/en active Active
- 2017-06-20 CY CY20171100647T patent/CY1119042T1/el unknown
2018
- 2018-05-02 US US15/968,941 patent/US10399982B2/en active Active
2019
- 2019-04-29 US US16/397,697 patent/US11208409B2/en active Active
2021
- 2021-11-10 US US17/523,838 patent/US11958854B2/en active Active
2024
- 2024-02-21 US US18/583,293 patent/US20250034143A1/en active Pending

Also Published As

Publication number	Publication date
ES2636835T7 (es)	2018-11-20
US20170305910A1 (en)	2017-10-26
CN105143229A (zh)	2015-12-09
US20160237089A1 (en)	2016-08-18
TWI609867B (zh)	2018-01-01
ES2636835T3 (es)	2017-10-09
US10399982B2 (en)	2019-09-03
US9969736B2 (en)	2018-05-15
HUE033528T2 (hu)	2017-12-28
AU2014228206B2 (en)	2018-05-10
US20140275071A1 (en)	2014-09-18
BR112015021164A8 (pt)	2019-12-03
SI2970303T1 (sl)	2017-08-31
PT2970303T (pt)	2017-06-23
US20250034143A1 (en)	2025-01-30
MX2015011617A (es)	2016-04-25
JP2016513717A (ja)	2016-05-16
JP6360149B2 (ja)	2018-07-18
AU2014228206A1 (en)	2015-09-24
HUE033528T4 (en)	2018-05-02
HK1217329A1 (zh)	2017-01-06
US20230040259A1 (en)	2023-02-09
EP2970303B9 (en)	2017-09-20
PE20151779A1 (es)	2015-11-20
EP2970303B1 (en)	2017-05-10
EA028815B1 (ru)	2018-01-31
NZ711718A (en)	2020-05-29
PL2970303T3 (pl)	2017-08-31
BR112015021164A2 (pt)	2017-07-18
DK2970303T3 (en)	2017-06-26
PH12015502141A1 (en)	2016-01-25
AU2014228206C1 (en)	2018-10-25
PL2970303T6 (pl)	2018-12-31
CN105143229B (zh)	2017-06-30
HRP20170840T4 (hr)	2018-11-16
EP2970303A2 (en)	2016-01-20
UA117470C2 (uk)	2018-08-10
US9359359B2 (en)	2016-06-07
IL240216B (en)	2018-11-29
EP2970303B3 (en)	2018-08-01
DK2970303T5 (en)	2018-01-02
WO2014143799A3 (en)	2014-11-06
MX370372B (es)	2019-12-11
MY189912A (en)	2022-03-21
DK2970303T6 (en)	2018-10-08
SG11201506479TA (en)	2015-09-29
WO2014143799A9 (en)	2014-12-24
US20190322667A1 (en)	2019-10-24
WO2014143799A4 (en)	2015-02-12
CN107082782A (zh)	2017-08-22
WO2014143799A2 (en)	2014-09-18
CN107082782B (zh)	2020-03-20
UY35488A (es)	2014-10-31
US20180244674A1 (en)	2018-08-30
CA2899646C (en)	2021-08-31
CY1119042T1 (el)	2018-01-10
TW201533044A (zh)	2015-09-01
LT2970303T (lt)	2017-07-25
PH12015502141B1 (en)	2018-10-12
EA201591615A1 (ru)	2016-05-31
IL240216A0 (en)	2015-09-24
KR102227629B1 (ko)	2021-03-16
US11208409B2 (en)	2021-12-28
CL2015002738A1 (es)	2016-06-10
CA2899646A1 (en)	2014-09-18
KR20150133233A (ko)	2015-11-27
RS56066B1 (sr)	2017-10-31
HRP20170840T1 (hr)	2017-09-08
ZA201505414B (en)	2016-03-30
US11958854B2 (en)	2024-04-16

Publication	Publication Date	Title
HRP20170840T1 (hr)	2017-09-08	Supstituirani ksantini i metode njihove uporabe
IL290547A (en)	2022-04-01	Antibodies and methods of use
HK1223913A1 (zh)	2017-08-11	經取代的苯甲酰胺及其使用方法
GB2535360B (en)	2017-04-12	Methods of preparing polyhemiaminals and polyhexahydrotriazines
IL244495B (en)	2020-06-30	Anti-alpha-synuclein antibodies and methods of use
SG11201600028YA (en)	2016-02-26	Substituted aminopyrimidine compounds and methods of use
HK1225612A1 (zh)	2017-09-15	抗ly6e抗體及使用方法
HK1224307A1 (zh)	2017-08-18	原毒素- 變體及其使用方法
HK1218247A1 (zh)	2017-02-10	益生菌和使用方法
IL245272A0 (en)	2016-06-30	pif-transfected cells and methods of use
SG11201507389RA (en)	2015-10-29	Integration of hydro-dechlorination and hydro-regeneration